News - CD4 underexpression

7ms

Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study). (PubMed, Future Oncol)

Introduction: The Meet-URO 18 study is a multicentric study of patients with metastatic renal cell carcinoma receiving nivolumab in the second-line and beyond, categorized as responders (progression-free survival ≥ 12 months) and non-responders (progression-free survival < 3 months)...Responders' tumor tissue (n = 90; 55.9%) was associated with lower CD4 expression (p = 0.014), higher CD56 expression (p = 0.046) and higher CD8/CD4 ratio (p = 0.030). Expert opinion/commentary: The present work suggests the regulatory role of a subpopulation of T cells on antitumor response and identifies CD56 as a putative biomarker of immunotherapy efficacy.

7 months ago

Journal • PD(L)-1 Biomarker • IO biomarker • Metastases

PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • mTOR (Mechanistic target of rapamycin kinase) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • CD68 (CD68 Molecule) • FUT4 (Fucosyltransferase 4)

PD-L1 expression • NCAM1 expression • CD4 expression • CD4 underexpression • NCAM1 overexpression

Opdivo (nivolumab)

1year

Study of immunophenotypic characteristics, clinicopathological parameters and prognosis in gastric cancer microenvironment (PubMed, Zhonghua Yi Xue Za Zhi)

Gastric cancer tissues have complex immune microenvironment characteristics. The expression of CD4, TIM3 and Foxp3 is closely related to the prognosis of patients.

1 year ago

Journal

CD8 (cluster of differentiation 8) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3)

CD8 expression • HAVCR2 expression • CD4 expression • CD4 overexpression • CD4 underexpression • FOXP3 expression

2years

Effect of CD4-positive T lymphocyte expression rate on pain control and prognosis in stage Ⅳ non-small cell lung cancer patients with cancerous pain (PubMed, Zhonghua Yi Xue Za Zhi)

The OS time and PFS time in the CD4 high expression group [M (Q, Q)] were 12.5 (8.1, 13.8) months and 8.5(3.1, 9.4) months, respectively, which were higher than those in the CD4 low expression group [8.6 (4.1, 12.9) months and 6.5 (2.1, 7.9) months, respectively] (all P<0.01). Cox multivariate analysis showed that high expression of CD4 was a protective factor affecting OS (HR=0.876, 95%CI: 1.224-6.641, P=0.004) and PFS (HR=0.675, 95%CI: 1.742-5.930, P=0.031) The stage Ⅳ NSCLC patients with cancerous pain and high expression of CD4-positive T lymphocytes have shorter pain control time, less morphine dosage, and longer OS and PFS time.

2 years ago

Retrospective data • Journal

CD4 (CD4 Molecule)

CD4 expression • CD4 underexpression • CD4 positive